On 7 JULY Karyopharm Therapeutics Inc (NASDAQ:KPTI) reported ($0.46) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.47) by $0.01. Analysts expect that Karyopharm Therapeutics will post $-2.00 EPS for the current fiscal year. Karyopharm Therapeutics Inc (NASDAQ:KPTI) weekly performance is -13.91%. On last trading day company shares ended up $38.01. Analysts mean target price for the company is $50.50. Karyopharm Therapeutics Inc (NASDAQ:KPTI) distance from 50-day simple moving average (SMA50) is 18.69%.
On 17 JUNE Fibrocell Science Inc (NYSEMKT: FCSC) announced that it has entered into an exclusive license agreement with The Regents of the University of California. Under the agreement, Fibrocell acquired the rights to commercially apply patented discoveries and technologies resulting from the ongoing scientific collaboration between the University of California at Los Angeles (UCLA) and Fibrocell Science. Fibrocell Science Inc (NYSEMKT: FCSC) shares fell -4.70% in last trading session and ended the day on $3.45. FCSC return on assets is -84.90%. Fibrocell Science Inc (NYSEMKT: FCSC) quarterly performance is -28.27%.
On 10 JUNE Adamas Pharmaceuticals Inc (NASDAQ:ADMS) presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson’s disease unable to perform routine daily tasks. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares moved down -1.94% in last trading session and was closed at $16.69, while trading in range of $16.16 – $17.38. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) year to date (YTD) performance is 19.13%.
Evoke Pharma Inc (NASDAQ:EVOK) ended the last trading day at $7.50. Company weekly volatility is calculated as 8.41% and price to cash ratio as 2.10. Evoke Pharma Inc (NASDAQ:EVOK) showed a negative weekly performance of -2.09%.
Sophiris Bio Inc (NASDAQ:SPHS) weekly performance is 19.64%. On last trading day company shares ended up $2.68. Analysts mean target price for the company is $8.63. Sophiris Bio Inc (NASDAQ:SPHS) distance from 50-day simple moving average (SMA50) is -4.15%.
Leave a Reply